Skip to main
OCGN

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen Inc. is focused on innovative gene and cell therapies, specifically targeting unmet medical needs in retinal diseases through its Modifier Gene Therapy Platform, which aims to address conditions like inherited retinal diseases and multifactorial diseases. The company's financial commitment to research and development is evidenced by an increase in R&D expenses from $32.1 million in FY24 to $39.8 million in FY25, indicating a robust investment in advancing its therapeutic pipeline. Furthermore, the promising clinical trial results demonstrating significant improvements in GA lesion size and growth signal potential efficacy benefits that could enhance Ocugen's competitive position in the biotech market.

Bears say

Ocugen Inc. faces significant challenges that contribute to a negative outlook, primarily due to its therapeutic pipeline's inability to consistently meet efficacy endpoints in clinical trials, coupled with emerging safety signals in its candidates. The company is also susceptible to commercial and competitive risks, with potential limitations on market access and reimbursement that could restrict the commercial viability of its products. Additionally, concerns regarding regulatory approval processes, manufacturing capabilities, and the company's ability to secure sufficient capital for ongoing program development further exacerbate the bleak financial outlook.

Ocugen, Inc. (OCGN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.